Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prokidney Corp (PROK)

Prokidney Corp (PROK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 588,736
  • Shares Outstanding, K 301,916
  • Annual Sales, $ 890 K
  • Annual Income, $ -68,990 K
  • EBIT $ -165 M
  • EBITDA $ -158 M
  • 60-Month Beta 1.84
  • Price/Sales 659.28
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 228.98% (+10.13%)
  • Historical Volatility 78.57%
  • IV Percentile 53%
  • IV Rank 10.35%
  • IV High 1,449.21% on 04/15/25
  • IV Low 88.15% on 01/07/26
  • Expected Move (DTE 3) 0.1275 (6.68%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 65
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 10,267
  • Open Int (30-Day) 9,727
  • Expected Range 1.7825 to 2.0375

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.13
  • Number of Estimates 3
  • High Estimate $-0.12
  • Low Estimate $-0.15
  • Prior Year $-0.13
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5600 +22.44%
on 03/30/26
2.3050 -17.14%
on 03/16/26
-0.3400 (-15.11%)
since 03/13/26
3-Month
1.5600 +22.44%
on 03/30/26
2.6050 -26.68%
on 03/10/26
-0.3700 (-16.23%)
since 01/14/26
52-Week
0.5400 +253.70%
on 06/30/25
7.1300 -73.21%
on 07/09/25
+1.1700 (+158.11%)
since 04/14/25

Most Recent Stories

More News
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney...

PROK : 1.9100 (-2.05%)
ProKidney Reports Full Year 2025 Financial Results and Business Highlights

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 In a July 2025 Type B meeting, aligned...

PROK : 1.9100 (-2.05%)
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK)  (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney...

PROK : 1.9100 (-2.05%)
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025 More than half of...

PROK : 1.9100 (-2.05%)
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progression Bilateral kidney...

PROK : 1.9100 (-2.05%)
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK)  (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic...

PROK : 1.9100 (-2.05%)
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025

WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK)  (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic...

PROK : 1.9100 (-2.05%)
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference

WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK)  (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic...

PROK : 1.9100 (-2.05%)
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

FDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with type 2 diabetes...

PROK : 1.9100 (-2.05%)
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetes FDA also confirmed that the ongoing Phase 3 PROACT 1 study...

PROK : 1.9100 (-2.05%)

Business Summary

ProKidney LP is a late clinical-stage cellular therapeutics company focused on CKD. The company's lead product candidate includes REACT(TM) is a first-of-its-kind, patented disease-modifying autologous cellular therapy. ProKidney LP, formerly known as Suvretta Holdings Corp. III, is based in WINSTON-SALEM,...

See More

Key Turning Points

3rd Resistance Point 2.1350
2nd Resistance Point 2.0800
1st Resistance Point 1.9950
Last Price 1.9100
1st Support Level 1.8550
2nd Support Level 1.8000
3rd Support Level 1.7150

See More

52-Week High 7.1300
Fibonacci 61.8% 4.6126
Fibonacci 50% 3.8350
Fibonacci 38.2% 3.0574
Last Price 1.9100
52-Week Low 0.5400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.